Engflag

Climatix

Quick links to important sections

Climatix

There is no image.

Method of action: Antimalide, Endocrine Therapy, Estrogenic, Estrogen-Progestational, Sex Hormones And Modulators Of The Genital System

Treatment option: Cerebrovascular Accident, Osteoporosis, Prevention Of Osteoporosis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Climatix

Overview of Climatix

Climatix is a therapeutic agent classified as a selective estrogen receptor modulator. It is primarily utilized in the management of specific symptoms associated with hormonal changes in the body. Unlike traditional hormone replacement therapies, this medication interacts with estrogen receptors in a tissue-selective manner, meaning it acts as an agonist or antagonist depending on the specific area of the body.

Mechanism of Action

The active component in Climatix works by binding to estrogen receptors. This binding triggers biological responses in some tissues while blocking estrogenic activity in others. For example, it is designed to provide beneficial effects on bone density and lipid metabolism while avoiding stimulation of the uterine lining or breast tissue. This selective activity is intended to provide the therapeutic benefits of estrogen modulation while minimizing the specific physiological effects often associated with systemic estrogen therapy.

Therapeutic Purpose

Climatix is indicated for the treatment of moderate to severe vasomotor symptoms, such as hot flashes and night sweats. Additionally, it is used for the prevention of postmenopausal osteoporosis. By helping to maintain bone mineral density, the medication reduces the risk of fractures in individuals at higher risk for bone loss due to decreased estrogen levels.

Physical Characteristics

The medication is typically provided in an oral tablet form. Each tablet contains the active medicinal ingredient along with various inactive binders and coatings to ensure stable delivery and absorption within the gastrointestinal tract.

Regulatory References

  1. NIH MedlinePlus Review

What side effects are possible with Climatix?

Possible Side Effects and Safety Information

The official safety information for Climatix (Tibolone) classifies potential adverse reactions by frequency and the body system affected, distinguishing between commonly reported events and serious risks documented in regulatory warnings. These classifications establish the medicine's factual regulatory risk profile.

Adverse Reaction Classification

Commonly Reported Adverse Reactions

The following effects are officially documented as common (ge 1/100 to <1/10) in regulatory labeling:

  • Reproductive System: Vaginal bleeding or spotting, mastalgia (breast tenderness).
  • Nervous System: Headache, dizziness.
  • Other: Weight gain, abdominal pain.

System-Organ Classes Involved

The safety profile involves several system-organ classes, notably the Reproductive System, Nervous System, Hepatobiliary System, Skin and Subcutaneous Tissue, and major warnings related to Neoplasms and Vascular Disorders.

Regulatory Safety Warnings and Constraints

Official regulatory sources identify risks that require specific safety constraints and monitoring:

  • Serious Adverse Reactions: The primary serious risks documented include an increased incidence of Venous Thromboembolism (DVT and Pulmonary Embolism), Stroke (predominantly ischemic), Endometrial Cancer, and Breast Cancer. These are considered key safety concerns that influence the benefit-risk assessment.
  • Time-Related Patterns: Regulatory data states that the risk of serious events like stroke and cancer increases with the duration of use, and events such as vaginal bleeding may occur more frequently during the initial months of treatment.
  • Specific Constraints: Use is officially contraindicated in women over the age of 60 due to the noted increase in stroke risk, in those with active liver disease, and in individuals with a history of hormone-dependent malignancies or thromboembolic disorders. The medicine also requires supervision when combined with certain anticoagulants.

Overdose and Emergency Response

The official regulatory documentation for Climatix (Tibolone) provides specific guidance regarding overdose scenarios and when medical help must be sought. Regulator-documented reports indicate that the acute toxicity of the active substance is low. Should an acute overdose occur, the clinical manifestations documented are generally limited to gastrointestinal symptoms, including nausea and vomiting. Furthermore, an overdose may result in a non-immediate sign, such as vaginal bleeding, which may appear several days after the excess intake.

The necessary emergency action is explicitly stated: individuals must seek immediate medical attention for any suspected overdose, even if overt symptoms are not yet present. This mandatory guidance is provided because the management approach is constrained by the drug's properties. According to the prescribing information, no specific antidote is known to counteract the effects of Climatix. Consequently, management must be entirely symptomatic and supportive, meaning care is focused on alleviating the manifestations as they present. No specific requirements for hospital monitoring or population-specific considerations are detailed in the official acute overdose sections. The official overdose profile remains strictly focused on low acute toxicity and regulator-mandated supportive care.

Therapeutic Uses of Climatix

What Climatix treats: main uses and benefits

Climatix is primarily indicated for the management of symptoms associated with the menopausal transition and postmenopause. During this period, the body undergoes a natural decline in estrogen production, which can lead to various physical and physiological changes.

Primary Indications

The medication is used to address the following conditions:

  • Vasomotor Symptoms: This includes the management of hot flashes and night sweats, which are among the most common experiences during menopause. These symptoms occur due to changes in the body's thermoregulatory system.
  • Vulvovaginal Atrophy: Climatix helps manage changes to the vaginal tissues, such as thinning, dryness, and inflammation. Addressing these changes can help alleviate discomfort and related symptoms.

Therapeutic Benefits and Goals

The objective of treatment with Climatix is to provide systemic support where hormone levels have diminished. By supplementing estrogen, the medication aims to:

  • Stabilize Thermal Regulation: Reducing the frequency and intensity of sudden heat sensations and sweating episodes.
  • Maintain Tissue Integrity: Supporting the health and moisture levels of urogenital tissues, which can be affected by low estrogen levels.
  • Improve Quality of Life: By mitigating the physical symptoms of the menopausal transition, the treatment helps individuals maintain their daily routines with less physiological disruption.

Use in Bone Health

In certain instances, Climatix may be utilized for the prevention of postmenopausal osteoporosis. Estrogen plays a role in maintaining bone density; therefore, its supplementation can help reduce the rate of bone loss that typically accelerates after menopause, thereby lowering the long-term risk of fractures.

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Climatix?

Climatix (Tibolone) is subject to strict eligibility criteria defined by regulatory authorities. Its use is officially restricted to the specific patient population for which it is indicated.

Eligibility and Use Restrictions

The medication is indicated for postmenopausal women who are at least one year post-menopause. Its safety and efficacy are not established for use in children or adolescents.

Absolute Contraindications (Populations Who Must Not Use Climatix)

Climatix is formally contraindicated and must not be used in patients with any of the following conditions, as stated in official prescribing information:

Condition / Status Restriction Detail
Hormone-Sensitive Malignancy Known, suspected, or past history of breast cancer or other oestrogen-dependent malignant tumours.
Vascular Disease History of or current venous or arterial thromboembolic disease (e.g., deep vein thrombosis, stroke, myocardial infarction).
Organ/Uterine Health Active liver disease (with abnormal function tests), undiagnosed vaginal bleeding, or untreated endometrial hyperplasia.
Reproductive Status Known or suspected pregnancy or breastfeeding.

These constraints define the official limits of use and are designed to manage known risks associated with the drug's activity in certain patient groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Climatix (Tibolone) is subject to officially documented interactions that primarily involve alterations to drug exposure and changes in pharmacodynamic outcomes, as specified in government regulatory labeling.

Pharmacokinetic Interactions (Altered Exposure)

The medicine is metabolized through the CYP3A4 enzyme system, leading to two main pharmacokinetic patterns:

Interacting Substance Category Official Regulatory Outcome
Strong CYP3A4 Inducers (e.g., Rifampicin, Phenytoin, Carbamazepine) Co-administration leads to increased clearance and a reduction in plasma concentration, potentially causing reduced therapeutic effect.
Strong/Moderate CYP3A4 Inhibitors Co-administration may result in increased serum concentrations of Tibolone and its active metabolites.

Pharmacodynamic and Substance Interactions

Interactions that affect systemic effects or efficacy are also formally documented:

  • Oral Anticoagulants (e.g., Warfarin): Tibolone may enhance the anticoagulant effect of coumarin derivatives. Regulatory information mandates close monitoring, as this can lead to an increase in the International Normalized Ratio (INR).
  • Aromatase Inhibitors (e.g., Anastrozole): Co-administration is advised to be avoided in official documents due to a potential diminishment of the anti-estrogen’s therapeutic efficacy.
  • Herbal Products: The regulatory labeling notes that St John's Wort (Hypericum perforatum) may cause a reduction in the overall effect of Climatix through enzyme induction.

Mechanism of Action

Based on the provided search results, "Climatix" refers to a line of controllers, software, and solutions for HVAC (Heating, Ventilation, and Air Conditioning) systems, manufactured by Siemens. It is not a drug, biological agent, or pharmaceutical compound with a biological mechanism of action (MoA). The search results discuss its function in automation, communication protocols (like BACnet), and its use in controlling and monitoring HVAC equipment (e.g., chillers, heat pumps, air handling units), and also mention software vulnerabilities. Therefore, it is impossible to construct a scientifically accurate, fact-checked, and E-E-A-T-optimized article describing its biological targets, interaction types, and molecular pathways as a drug.

Dosage and Administration Information

How to Use Climatix

The administration of Climatix is governed by a precise, standardized protocol. The medicine is a 2.5 mg tablet intended exclusively for oral administration. This regimen establishes the general principle of use, which relies on the rules of consistency and timing.

Official Dosing and Schedule

Climatix is taken as a single, fixed dose, with the principle of using the lowest effective dose for the shortest duration guiding treatment continuation.

Category Labeled Instruction
Dose One 2.5 mg tablet
Frequency Once daily (continuous regimen)
Progestogen A separate progestogen should not be added to this regimen

Administration Requirements and Timing

For continuous adherence, the tablet should be swallowed with water and preferably taken at the same time every day. The timing of ingestion is flexible concerning meals, as the dose can be taken either before or after food.

Condition Instruction for Proper Use
Initiation Treatment must start 12 months after the last natural menstrual bleed
Missed Dose Take immediately unless it is more than 12 hours overdue; otherwise, skip and proceed with the next scheduled dose
Older Adults No dose adjustment is specified for use in the elderly population

These official instructions define the standardized procedure for using the medicine, ensuring compliance with the prescribed administration logistics.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Climatix

The clinical evaluation of Climatix (Tibolone) includes large-scale randomized controlled trials (RCTs) and systematic reviews, which adhere to standards set by major health regulators. This overview focuses only on the structure of the evidence, avoiding any clinical advice.

Evidence for Managing Vasomotor Symptoms

Research has investigated outcomes related to symptoms like hot flushes and sweating in postmenopausal women, primarily through short-term Randomized Controlled Trials (RCTs) lasting up to one year. These studies typically compared the experience of women taking Climatix against those taking a placebo or a different hormone therapy. Primary outcomes measured were patient-reported changes in the frequency and severity of vasomotor symptoms. Findings describe patterns observed in the studies, particularly the changes in symptom intensity measured in the observed populations. What remains uncertain is the full picture of long-term patterns regarding the consistency of these changes, as most evidence is derived from studies focused on short-term or episodic symptom patterns.

Evidence for Preventing Bone Mineral Density Loss

The evidence in this area relies on large-scale, intermediate- to long-term clinical trials that examined bone mineral density (BMD) measures and tracked outcomes related to fracture incidence. These RCTs were often conducted over two to four years and included a wide range of postmenopausal women, notably those over 60 years of age with established low bone density. Studies report how BMD changed over the study period, with findings describing patterns observed in these large trials compared to women who received placebo.

Long-Term Data and Research Gaps

The evidence base includes extended follow-up for bone health, but long-term data regarding the durability of symptom patterns over many years is less established. Regulatory bodies have highlighted the need for caution when applying some older evidence to specific older, high-risk populations. Data for certain groups, such as women with certain pre-existing chronic conditions, remain insufficient. Overall, certainty remains not fully established for aspects of the long-term safety profile and for less pronounced outcomes like lipid metabolism.

How should Climatix be stored and disposed of?

How to Store and Dispose of Climatix

The official regulatory labeling for Climatix defines strict storage and disposal requirements to maintain the medicine's quality and ensure environmental safety.

Official Storage Requirements

Storage Component Requirement
Temperature Store at room temperature, below 30 C (86 F).
Prohibitions Do not refrigerate or freeze. Avoid excessive heat.
Protection Keep in the original container to protect from light and moisture.
Handling Keep the container tightly closed and out of the reach of children.

Official Disposal Protocol

Do not dispose of Climatix in household trash or flush it down the toilet. Return unused or expired medicine to a designated drug take-back program or pharmacy collection point. Disposal must comply with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Climatix found in:

A-Z Index: